Articles

Compensation for research-related injury in South Africa: A critique of the good clinical practice (GCP) guidelines

C Slack, P Singh, A Strode, Z Essack

Abstract


This article examines the current South African Department of Health Good Clinical Practice (2006) guideline recommendations regarding compensation for harm incurred in clinical trials. It applies the case of a phase IIb HIV vaccine trial in South Africa, for which enrolments and vaccinations were suspended early, based on data from an international companion study that indicated no evidence of efficacy and greater susceptibility to HIV infection in a subgroup of vaccinees. The case application indicates certain substantive and procedural limitations within the African Department of Health Good Clinical Practice (2006) guideline recommendations on compensation for harm, which should be re-considered in order to improve protections for trial participants.

Authors' affiliations

C Slack, HIV/AIDS Vaccines Ethics Group, University of KwaZulu-Natal, Durban

P Singh, Faculty of Law, University of KwaZulu-Natal

A Strode, Faculty of Law, University of KwaZulu-Natal

Z Essack, HIV/AIDS Vaccines Ethics Group, University of KwaZulu-Natal, Durban

Full Text

PDF (67KB) HTML

Keywords

Compensation for harm; ethics; HIV vaccine trials

Cite this article

South African Journal of Bioethics and Law 2012;5(2):91-94. DOI:10.7196/SAJBL.211

Article History

Date submitted: 2012-04-23
Date published: 2012-11-23

Article Views

Abstract views: 2570
Full text views: 4692

Comments on this article

*Read our policy for posting comments here